A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers
The primary purpose of this study is to assess the tolerability of prexasertib in Japanese participants with advanced solid cancers.
Neoplasm
DRUG: Prexasertib
Number of Participants with Prexasertib Dose-Limiting Toxicities (DLT), Cycle 1 (14 day cycle)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Prexasertib, Pre-dose up to 7 Days Post Treatment in Cycle 1/2 (Approximately 7 Days)|Pharmacokinetics (PK): Area Under Curve (AUC) of Prexasertib, Pre-dose up to 7 Days Post Treatment in Cycle1/2 (Approximately 7 Days)|Percentage of Participants with a Tumor Response, Baseline to Study Completion (Approximately 24 weeks)
The primary purpose of this study is to assess the tolerability of prexasertib in Japanese participants with advanced solid cancers.